Scientists identify FNIP1 gene mutation mimicking Ozempic's effects on obesity

Scientists have identified a rare gene mutation that appears to mimic the effects of the popular diabetes drug Ozempic, potentially offering new insights into weight management and metabolic health. This discovery centers on the FNIP1 gene, which influences how the body burns energy. Approximately one in 7,000 individuals carries a defective version of this gene, which enhances calorie burning and reduces the likelihood of obesity, diabetes, and other metabolic diseases.

Research into FNIP1 began with a comprehensive analysis of the DNA of over a million people across three continents. The investigation aimed to pinpoint genetic mutations that affect fat storage and energy usage. The FNIP1 mutation stood out for its significant role in metabolism. When functioning normally, FNIP1 works with a protein called folliculin to slow down energy consumption, conserving resources during times of food abundance. However, a malfunctioning FNIP1 gene leads to increased energy expenditure and fat utilization, according to Viktoria Gusarova, a researcher at Regeneron Pharmaceuticals and a co-author of the study.

In the study, researchers found that individuals with the FNIP1 mutation exhibited lower levels of blood lipids, reduced liver fat, and significantly lower blood sugar levels. They also showed about a 60 percent decrease in the risk of developing cardiometabolic diseases compared to those without the mutation. The findings suggest that these individuals are more efficient at consuming, storing, and utilizing energy, which serves as a protective factor against various health issues, as explained by geneticist Luca Lotta.

The implications of this research could be substantial. By silencing FNIP1 in laboratory settings, scientists observed enhanced fat-burning activity in liver cells and improved insulin sensitivity in mice fed a high-fat diet. This approach not only curtailed weight gain but also prevented liver damage associated with such diets. The mutation's rarity highlights an evolutionary lag, as our calorie-rich modern environment contrasts sharply with historical dietary patterns. The researchers hope this discovery may pave the way for new therapeutic approaches in treating obesity and related conditions.